History
- 2021.04. Establishment of Actcellbio company
- 2021.07. Establishment of Gangnam Medical Clinic Research Institute, KOITA's "Study on Platelet Activation"
- 2022.03. Development of activation-related products for blood separation
- 2023.07. Completion of KOITA's "Study on Platelet Activation"
- 2023.08. Grade III Blood Treatment Instruments (ACT PRF) Permission
- 2024.03. Grade 3 KGMP certification
- 2024.06. Grade 3 blood treatment instrument (ACT PRPD) authorization
- 2024.07. U.S. FDA certification for blood activation equipment
- 2024.07. Authorization for Grade III Bone marrow Treatment Instruments (ACT BMS30)
